MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-30-2026
Baxter International Cash Flow 2011-2026 | BAX
Annual Cash Flow Baxter International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
845 M | 1.02 B | 1.73 B | 1.21 B | 2.22 B | 1.87 B | 2.1 B | 2.02 B | 1.71 B | 1.65 B | 1.77 B | 3.22 B | 3.2 B | 3.11 B | 2.82 B |
Depreciation & Amortization |
981 M | 997 M | 984 M | 1.07 B | 867 M | 823 M | 789 M | 771 M | 750 M | 800 M | 759 M | 792 M | 635 M | 712 M | 670 M |
Accounts Payables |
999 M | 968 M | 881 M | 1.11 B | 1.25 B | 1.04 B | 892 M | 1 B | 920 M | 791 M | 716 M | 1.26 B | 1.1 B | 766 M | 795 M |
Accounts Receivables |
1.7 B | 1.54 B | 1.54 B | 2.34 B | 2.4 B | 1.7 B | 1.8 B | 1.7 B | 1.79 B | 1.69 B | 1.73 B | 2.8 B | 2.91 B | 2.42 B | 2.42 B |
Total Inventories |
2.23 B | 2.05 B | 1.92 B | 2.68 B | 2.45 B | 1.92 B | 1.65 B | 1.65 B | 1.48 B | 1.43 B | 1.6 B | 3.56 B | 3.5 B | 2.8 B | 2.63 B |
All numbers in USD currency
Quarterly Cash Flow Baxter International
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
213 M | - | - | -193 M | - | - | 163 M | - | - | 479 M | - | 772 M | - | 208 M | - | 1.53 B | - | 377 M | - | 1.16 B | 646 M | 272 M | - | 1.28 B | 574 M | 128 M | - | 1.31 B | 852 M | 430 M | - | 1.32 B | 718 M | 189 M | - | 941 M | 409 M | -333 M | - | 1.05 B | 792 M | 96 M | - | 2.07 B | 1.16 B | 559 M | - | 2.12 B | 1.15 B | 386 M | - | 2.16 B | 1.41 B | 446 M | - | 1.92 B | 1 B | 371 M |
Depreciation & Amortization |
237 M | 90 M | 106 M | 247 M | 95 M | 73 M | 271 M | 147 M | 157 M | 313 M | - | 168 M | 193 M | 380 M | - | 645 M | 67 M | 217 M | - | 610 M | 401 M | 199 M | - | 580 M | 385 M | 192 M | - | 586 M | 387 M | 190 M | - | 562 M | 378 M | 194 M | - | 599 M | 395 M | 189 M | - | 593 M | 377 M | 187 M | - | 592 M | 489 M | 236 M | - | 573 M | 366 M | 183 M | - | 534 M | 355 M | 175 M | - | 503 M | 327 M | 158 M |
Accounts Payables |
1.09 B | 953 M | 995 M | 963 M | 841 M | 1.25 B | 1.33 B | 1.25 B | 1.24 B | 1.29 B | 1.11 B | 1.23 B | - | 1.22 B | 1.25 B | 999 M | 1 B | 1.02 B | 1.04 B | 1.04 B | 1.04 B | 1.04 B | 892 M | - | - | - | 998 M | - | - | - | 920 M | - | - | - | 791 M | - | - | - | 716 M | - | - | - | 677 M | - | - | - | 1.1 B | - | - | - | 766 M | - | - | - | 795 M | - | - | - |
Accounts Receivables |
1.54 B | 1.64 B | 1.62 B | 1.49 B | 1.54 B | 2.37 B | 2.26 B | 2.28 B | 2.27 B | 2.3 B | 2.34 B | 2.3 B | - | 2.3 B | 2.4 B | 1.8 B | 1.8 B | 1.6 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.69 B | 1.69 B | 1.69 B | 1.69 B | 1.73 B | 1.73 B | 1.73 B | 1.73 B | 1.88 B | 1.88 B | 2.8 B | 2.8 B | 2.91 B | 2.91 B | 2.91 B | 2.91 B | 2.42 B | 2.42 B | 2.42 B | 2.42 B | 2.42 B | 2.35 B | 2.49 B | 2.4 B |
Total Inventories |
2.32 B | 2.46 B | 2.38 B | 2.17 B | 2.1 B | 2.98 B | 2.99 B | 2.87 B | 2.9 B | 2.92 B | 2.68 B | 2.68 B | - | 2.55 B | 2.45 B | 2.02 B | 2.06 B | 2.02 B | 1.92 B | 1.92 B | 1.92 B | 1.92 B | 1.65 B | 1.65 B | 1.65 B | 1.65 B | 1.67 B | 1.67 B | 1.65 B | 1.65 B | 1.48 B | 1.48 B | 1.48 B | 1.48 B | 1.43 B | 1.43 B | 1.43 B | 1.43 B | 1.6 B | 1.6 B | 1.6 B | 1.6 B | 1.58 B | 1.58 B | 3.56 B | 3.56 B | 3.5 B | 3.5 B | 3.5 B | 3.5 B | 2.8 B | 2.8 B | 2.8 B | 2.8 B | 2.63 B | 2.63 B | 2.63 B | 2.63 B |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company Baxter International , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Medical instruments sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Alcon
ALC
|
$ 74.45 | 1.32 % | $ 40.4 B |  Schweiz |
 |
The Cooper Companies
COO
|
$ 61.25 | -0.44 % | $ 12.2 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 11.8 | 1.29 % | $ 28.6 M | USA |
 |
electroCore
ECOR
|
$ 6.99 | 4.64 % | $ 59.3 K | USA |
 |
Haemonetics Corporation
HAE
|
$ 55.62 | 0.54 % | $ 2.8 B | USA |
 |
ICU Medical
ICUI
|
$ 117.01 | -1.4 % | $ 2.88 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 118.11 | -0.9 % | $ 3.78 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 451.38 | -0.21 % | $ 161 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 133.42 | -1.79 % | $ 6.46 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.08 | 2.26 % | $ 188 M | USA |
 |
Masimo Corporation
MASI
|
$ 178.58 | 0.21 % | $ 9.52 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 10.62 | 2.21 % | $ 219 M | USA |
 |
Microbot Medical
MBOT
|
$ 2.1 | -0.47 % | $ 96.2 M |  Israel |
 |
Milestone Scientific
MLSS
|
$ 0.4 | 12.14 % | $ 32.8 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 60.44 | -2.53 % | $ 3.58 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 26.19 | 1.47 % | $ 4.4 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 18.65 | -6.89 % | $ 1.26 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.72 | 9.25 % | $ 21.6 M | USA |
 |
Pro-Dex
PDEX
|
$ 56.0 | 9.31 % | $ 184 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 112.0 | 0.42 % | $ 2.54 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 27.45 | 0.59 % | $ 1.36 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
STERIS plc
STE
|
$ 212.97 | 0.34 % | $ 21 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 120.69 | 0.67 % | $ 5.39 B | USA |
 |
BioLife Solutions
BLFS
|
$ 21.55 | 2.18 % | $ 993 M | USA |
 |
Stereotaxis
STXS
|
$ 1.92 | 1.05 % | $ 175 M | USA |
 |
ResMed
RMD
|
$ 207.88 | -0.74 % | $ 30.4 B | USA |
 |
AtriCure
ATRC
|
$ 29.44 | 2.29 % | $ 1.41 B | USA |
 |
Utah Medical Products
UTMD
|
$ 64.86 | 0.32 % | $ 210 M | USA |
 |
Harvard Bioscience
HBIO
|
$ 6.63 | 3.59 % | $ 294 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 309.97 | 3.26 % | $ 22.4 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 11.37 | 1.52 % | $ 2.27 B | USA |
 |
AngioDynamics
ANGO
|
$ 10.96 | -0.18 % | $ 448 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 144.17 | -1.5 % | $ 41.5 B | USA |
 |
Nephros
NEPH
|
$ 3.14 | 2.28 % | $ 32.6 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.0 | 1.69 % | $ 220 M | USA |
 |
Repligen Corporation
RGEN
|
$ 125.61 | 6.26 % | $ 7 M | USA |